ARTICLE | Company News
Canopus, WARF deal
June 23, 2008 7:00 AM UTC
WARF granted Canopus exclusive rights to IP covering the company’s CB1400, which is in Phase II testing to treat mucositis in patients receiving radiotherapy or chemotherapy. Further terms were not d...